---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-000883"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T10:24:35.082817+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B

## Summary
- Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).
- GAAP net income $563.9M includes $569M tax benefit from valuation allowance release; non-GAAP diluted EPS $0.10.
- Opzelura launch: ~19,000 patients treated in Q4; vitiligo sNDA under Priority Review with PDUFA April 18, 2022.
- Parsaclisib NDA withdrawn for FL/MZL/MCL in U.S.; baricitinib SLE Phase 3 discontinued; baricitinib AD sNDA faces potential CRL.
- 2022 guidance: Jakafi $2.3-2.4B, other heme/onc $210-240M; GAAP R&D $1.55-1.59B, SG&A $950M-1B.

## SEC filing metadata
- accession: 0001558370-22-000883
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/0001558370-22-000883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/incy-20220208x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-000883
- JSON: https://secwatch.observer/filing/0001558370-22-000883.json
- Plain text: https://secwatch.observer/filing/0001558370-22-000883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.